| mRNA |
GSK1070916 |
GDSC1000 |
pan-cancer |
AAC |
0.25 |
3e-15 |
| mRNA |
BX-912 |
GDSC1000 |
pan-cancer |
AAC |
0.23 |
4e-14 |
| mRNA |
barasertib |
CTRPv2 |
pan-cancer |
AAC |
0.25 |
5e-14 |
| mRNA |
Cytarabine |
CTRPv2 |
pan-cancer |
AAC |
0.22 |
4e-13 |
| mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
1e-10 |
| mRNA |
Doxorubicin |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
7e-10 |
| mRNA |
etoposide |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
9e-10 |
| mRNA |
clofarabine |
CTRPv2 |
pan-cancer |
AAC |
0.19 |
1e-09 |
| mRNA |
cabozantinib |
CTRPv2 |
pan-cancer |
AAC |
0.23 |
3e-09 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.2 |
6e-09 |